The biotin-peptide conjugate sold in thousands of hair products—built on GHK science, marketed as Procapil, and never once tested as a standalone ingredient in a controlled human trial

Biotinoyl tripeptide-1 is a semi-synthetic peptide created by attaching biotin—vitamin B7—to the N-terminus of GHK, a collagen-derived tripeptide with established wound-healing and tissue-remodeling activity. The resulting conjugate is positioned as a cosmeceutical ingredient for hair loss, most commonly marketed under the brand name Procapil in combination with oleanolic acid (a 5-alpha reductase inhibitor) and apigenin (an antioxidant flavonoid).

The engineering logic is appealing: GHK stimulates dermal papilla cells and strengthens the follicular extracellular matrix, while biotin—deficiency of which causes hair loss—might improve follicular uptake via sodium-dependent multivitamin transporters. The problem is that this targeting hypothesis has never been tested. No study has demonstrated that biotinylation improves GHK delivery to hair follicles compared to free GHK or GHK-Cu.

This article examines what the evidence actually supports, separates the parent peptide's biology from the conjugate's marketing, and explains why the gap between Procapil's clinical data and biotinoyl tripeptide-1's individual contribution matters for anyone considering this ingredient.

Quick Facts: Biotinoyl Tripeptide-1 at a Glance

What Is Biotinoyl Tripeptide-1?

Pronunciation: bye-OT-in-oil try-PEP-tide one

Your body makes a tiny signaling molecule called GHK every time collagen breaks down. This tripeptide—just three amino acids, glycine-histidine-lysine—acts as a biological repair signal: it tells nearby cells to make more collagen, ramp up growth factors, and begin rebuilding damaged tissue. GHK was first identified in human plasma by Loren Pickart in 1973, and decades of research have confirmed its role in wound healing, skin repair, and extracellular matrix remodeling.

Biotinoyl tripeptide-1 is an engineered version of GHK with biotin (vitamin B7) chemically attached to its N-terminus. The concept is dual-action: GHK provides the matrikine signaling to strengthen follicular tissue, while biotin—a vitamin essential for hair health in deficiency states—hitches a ride to the follicle via the same transporter system that carries biotin into cells.

It sounds elegant. The problem is that the biotinylation strategy has never been validated in published research. No study has demonstrated that attaching biotin to GHK improves follicular delivery compared to free GHK, GHK-Cu, or separate topical biotin. The assumption is untested.

Most consumers encounter biotinoyl tripeptide-1 through Procapil, a branded ingredient blend manufactured by BASF (formerly Lucas Meyer Specialties) that combines the peptide with oleanolic acid—a triterpene from olive leaves that inhibits 5-alpha reductase—and apigenin, a flavonoid antioxidant from chamomile. Every human study that appears to test "biotinoyl tripeptide-1" is actually testing this three-ingredient combination, making it impossible to isolate the peptide's contribution.

Origins and Discovery

GHK's story begins in 1973 when Loren Pickart, then at the University of California San Francisco, discovered that a fraction of human albumin stimulated liver cells to produce proteins associated with a younger phenotype. He isolated the active component: a tripeptide, glycyl-L-histidyl-L-lysine, that appeared to reset gene expression patterns in aging tissue. Pickart would spend the next four decades characterizing GHK's effects, eventually showing that it modulates the expression of over 4,000 human genes (PMID 18644225).

The biotin conjugation emerged from cosmetic chemistry rather than academic pharmacology. In the early 2000s, ingredient manufacturers—particularly Lucas Meyer Specialties (later acquired by BASF)—sought ways to reformulate known bioactive peptides for the cosmeceutical market. Biotin was an obvious partner for a hair-targeted product: vitamin B7 deficiency causes alopecia, and the beauty industry had already established biotin as a "hair vitamin" in consumer consciousness.

The resulting conjugate—biotinoyl tripeptide-1—was combined with oleanolic acid and apigenin and branded as Procapil. The product entered the market in the mid-2000s with manufacturer-generated efficacy data. That data has never been independently replicated.

Mechanism of Action

GHK Matrikine Signaling

GHK functions as a matrikine—a signaling peptide released during extracellular matrix remodeling that instructs surrounding cells to begin repair processes. In dermal fibroblasts, GHK at concentrations of 10–100 nM stimulates collagen I and collagen III gene expression, upregulates transforming growth factor-beta (TGF-beta) and fibroblast growth factor (FGF), and promotes integrin-mediated cell adhesion (PMID 11133367).

In the hair follicle context, this signaling would theoretically strengthen the follicular extracellular matrix, improve dermal papilla cell phenotype, and create a more anabolic microenvironment for hair growth. The related compound GHK-Cu (copper-bound GHK) has been shown to stimulate dermal papilla cell proliferation and hair follicle elongation in vitro (PMID 17703734), and to accelerate anagen re-entry in C57BL/6J mice after depilation (PMID 1809108).

The Biotin Targeting Hypothesis

The rationale for biotinylation rests on two premises: 1. Hair follicle cells express sodium-dependent multivitamin transporters (SMVT) that actively import biotin 2. Conjugating biotin to GHK would therefore enhance follicular uptake of the peptide payload

Neither premise has been validated for this specific conjugate. SMVT expression in follicular keratinocytes has been demonstrated, but whether the transporter recognizes biotin when it is covalently bound to a ~346 Da peptide—versus free biotin at ~244 Da—has not been studied. The assumption that a biotinylated peptide conjugate (~600 Da total) would be transported via the same mechanism as free biotin is pharmacologically speculative.

Additionally, the biotin "supplementation" component of the dual-action concept faces its own evidence problem: biotin supplementation only benefits hair in cases of biotin deficiency (PMID 28879195, PMID 39148962). For the majority of people experiencing androgenetic alopecia who are not biotin-deficient, the biotin moiety adds no established value.

Oleanolic Acid and Apigenin (Procapil Context)

Understanding biotinoyl tripeptide-1 requires understanding its commercial context. In Procapil, the peptide is combined with two botanical actives:

• Oleanolic acid is a pentacyclic triterpene from olive leaves that inhibits 5-alpha reductase—the enzyme that converts testosterone to dihydrotestosterone (DHT). DHT is the primary driver of androgenetic alopecia. Oleanolic acid's 5-alpha reductase inhibition provides a direct anti-androgenic mechanism independent of GHK's ECM remodeling.

• Apigenin is a flavonoid antioxidant from chamomile with anti-inflammatory properties. In the follicular microenvironment, it may reduce perifollicular inflammation—a contributing factor in progressive miniaturization.

This means any clinical effects observed with Procapil could be attributable to the anti-androgenic action of oleanolic acid, the anti-inflammatory effects of apigenin, or the ECM remodeling of GHK—or any combination thereof. Isolating the peptide's contribution is impossible without single-ingredient controlled trials that do not exist.

Key Research Areas and Studies

The Procapil Clinical Evidence

Three human studies have tested Procapil-containing formulations. None tested biotinoyl tripeptide-1 alone.

Study 1: Lucas Meyer Manufacturer Data (2006)

An open-label, uncontrolled study of 28 subjects with androgenetic alopecia applied Procapil topically for 6 months. Phototrichogram assessment showed a 12% increase in anagen/telogen ratio and 18% reduction in hair shedding versus baseline. This data was never published in a peer-reviewed journal; it exists only in manufacturer technical documents. Conflict of interest is substantial.

Study 2: Samadi et al. (2024, PMID 37990760)

An open-label study assessed a topical formulation containing caffeine and 3% Procapil for male pattern hair loss. Self-reported outcomes: 84.2% rated their hair loss as "improved" or "very improved." No side effects reported. Limitations: open-label, self-reported outcomes only, no objective hair count data, no placebo comparator.

Study 3: Procapil + PRP vs. Redensyl + PRP (2023, PMID 37292551)

A randomized controlled trial of 54 male patients with androgenetic alopecia compared Procapil + platelet-rich plasma (PRP) therapy to Redensyl + saw palmetto + biotin + PRP therapy. The Procapil + PRP group showed significantly higher researcher evaluation scores (64.7% vs. 25.5%), better photographic evaluation (88.9% vs. 60%), and higher self-evaluation scores. Four sessions at 3-week intervals.

This is the strongest study by design (randomized, comparative), but it tests a 4-ingredient combination plus PRP—any attribution to biotinoyl tripeptide-1 is speculative.

The Parent Peptide Evidence

The mechanistic case for biotinoyl tripeptide-1 rests entirely on the parent GHK and GHK-Cu literature:

• Pickart (PMID 11133367): GHK stimulates collagen synthesis in human dermal fibroblasts at 10–100 nM. Establishes the matrikine mechanism.
• Pyo et al. (PMID 17703734): AHK-Cu and GHK-Cu stimulate hair follicle elongation ex vivo and dermal papilla cell proliferation in vitro. The only study directly testing copper peptide complexes on human hair follicles.
• Uno & Kurata (PMID 1809108): GHK-Cu accelerates anagen re-entry in C57BL/6J mice after depilation. Animal model evidence for follicular activity.
• Liezmann et al. (PMID 21702037): GHK modulates immune privilege in human scalp follicles, reducing C3a/C5a complement activity—potentially relevant to alopecia areata.
• Pickart (PMID 18644225): GHK modulates expression of 4,000+ genes in human fibroblasts, including genes involved in tissue repair, antioxidant defense, and stem cell biology.

None of these studies tested the biotinylated conjugate. The extrapolation from GHK/GHK-Cu evidence to biotinoyl tripeptide-1 is an assumption, not a demonstrated fact.

Claims vs. Evidence

The Human Evidence Landscape

The human evidence landscape for biotinoyl tripeptide-1 is, in a precise sense, empty. No published study has tested the isolated compound in humans for any endpoint.

What exists is evidence for Procapil—a three-ingredient combination in which biotinoyl tripeptide-1 is one component alongside oleanolic acid and apigenin. Three studies exist, all with significant limitations:

The Manufacturer Study (2006)

The Lucas Meyer technical data—28 subjects, open-label, uncontrolled, 6 months—reports a 12% improvement in anagen/telogen ratio and 18% reduction in hair shedding. This data was never submitted for peer review. It exists in marketing materials. By Peptidings evidence standards, unpublished manufacturer data is the weakest form of clinical evidence.

Samadi et al. (2024, PMID 37990760)

Open-label. Self-reported outcomes only. No objective hair count. No comparator group. The formulation added caffeine—another active ingredient with independent hair growth evidence—making attribution even more complex.

Procapil + PRP RCT (2023, PMID 37292551)

The strongest design. Randomized, comparative, N=54. But the intervention arm combined Procapil with platelet-rich plasma—an established hair growth treatment with its own evidence base. The study cannot tell you whether Procapil contributed meaningfully to the PRP effect, let alone whether biotinoyl tripeptide-1 contributed to the Procapil effect.

The Attribution Problem

This is the defining challenge of biotinoyl tripeptide-1's evidence base. The compound is tested only in combinations—combinations that include independently active ingredients. Even if Procapil works, we cannot know whether the peptide contributes 80% of the effect, 5% of the effect, or is pharmacologically inert with the botanical components doing all the work. The only way to resolve this is a single-ingredient RCT. None has been conducted, and given the compound's cosmetic classification, none is likely to be.

Safety, Risks, and Limitations

Dermatological Safety

The safety profile of biotinoyl tripeptide-1 is the strongest aspect of its evidence base. Topical GHK and biotin have both been used in cosmetic formulations for decades with no significant adverse events reported. The Samadi 2024 study (PMID 37990760) specifically documented zero reports of dryness, itching, redness, flaking, folliculitis, or burning with Procapil 3%.

This is not surprising. The compound has a molecular weight of ~600 Da—large enough that percutaneous absorption through intact scalp skin is minimal. Any GHK that penetrates is rapidly degraded by serum peptidases. Systemic exposure is negligible.

The Biotin Assay Interference Issue

One safety consideration applies to the biotin component: high-dose biotin supplementation (typically oral, not topical) can interfere with immunoassays that use streptavidin-biotin chemistry. This can produce falsely low troponin readings (masking a heart attack) and falsely abnormal thyroid function tests. This risk applies primarily to people taking high-dose oral biotin supplements, not to topical cosmeceutical use where systemic biotin absorption is negligible. However, the issue deserves mention because some consumers use topical Procapil alongside oral biotin supplementation.

Limitations

The primary limitation is not safety—it is unknown efficacy. The compound is safe but unproven. Consumers paying premium prices for biotinoyl tripeptide-1–containing products are paying for a plausible mechanism, not demonstrated results. There is no safety concern that should prevent use, but there is an efficacy concern that should temper expectations.

Legal and Regulatory Status

Biotinoyl tripeptide-1 is classified as a cosmetic ingredient in the United States under 21 CFR Part 700. It is not regulated as a drug by the FDA, has no drug monograph, and no IND application has been filed. This means no regulatory body has evaluated the compound for safety or efficacy as a hair loss treatment.

In the EU, it is permitted under EC Regulation 1223/2009 (Cosmetics Regulation). The INCI name is registered. No therapeutic claims are permitted under EU cosmetics regulations.

The compound is not listed on the WADA Prohibited List. Its cosmetic classification means no sports regulatory concern exists.

Consumers should understand that cosmetic classification means the product can be sold without demonstrating efficacy. The manufacturer need only demonstrate that the product is safe and does not make drug claims. "Promotes thicker-looking hair" is a permissible cosmetic claim. "Treats hair loss" would be a drug claim requiring FDA approval.

Research Protocols and Formulation Considerations

Formulation

Biotinoyl tripeptide-1 is available in cosmeceutical formulations at concentrations typically ranging from 0.01% to 1%. In the Procapil blend, the peptide is combined with oleanolic acid and apigenin. Commercial products include serums, shampoos, conditioners, and leave-in scalp treatments.

Storage

Topical formulations should be stored at room temperature away from direct sunlight. The biotin conjugation improves resistance to aminopeptidase degradation compared to free GHK, contributing to formulation shelf-life stability. No reconstitution is required—these are ready-to-use cosmetic products.

Application Protocol (Based on Procapil Studies)

Studies used once-daily application to the scalp for 3–6 months. Consistent daily use appears necessary—the modest effect sizes observed in studies likely require sustained application to maintain any benefit.

Dosing in Published Research

The following table summarizes dosing protocols for Biotinoyl Tripeptide-1 as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.

No dose-response data exists for the isolated compound. Effective concentrations of biotinoyl tripeptide-1 within Procapil formulations are not publicly disclosed.

Dosing in Self-Experimentation Communities

Community use of biotinoyl tripeptide-1 is entirely topical and exclusively through commercial products. Unlike most compounds on Peptidings, there is no gray-market powder or injectable formulation. Users typically incorporate Procapil-containing serums into a layered hair care protocol:

Combination Stacks

Research into Biotinoyl Tripeptide-1 combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Biotinoyl Tripeptide-1 with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

Biotinoyl tripeptide-1 is a cosmetic ingredient with a plausible but unvalidated mechanism. The parent peptide GHK has genuine ECM-remodeling and growth factor–stimulating activity, established through decades of research. The biotinylation strategy—designed to enhance follicular targeting via SMVT transporters—has never been tested. Every human study tests Procapil, a three-ingredient combination, making it impossible to isolate the peptide's contribution. Effect sizes in Procapil studies are modest (5–18% improvement) and within placebo-response range for hair loss interventions.

The safety profile is excellent. No adverse events have been reported. The compound poses no meaningful risk. The question is not whether biotinoyl tripeptide-1 is safe—it is—but whether it is effective. That question remains unanswered.

For consumers: biotinoyl tripeptide-1 is a reasonable inclusion in a multi-product hair care regimen as a low-risk, low-cost adjunct. It is not a substitute for evidence-based hair loss treatments (minoxidil, finasteride, low-level laser therapy). Set expectations accordingly.

Verdict Recapitulation

Biotinoyl tripeptide-1 sits at Tier 4 because no controlled human trial has tested the isolated compound. The combination data (Procapil) cannot be attributed to any single ingredient. The verdict is Eyes Open because the underlying GHK biology is sound, the safety profile is clean, and the compound is not harmful—but the gap between the marketing narrative and the evidence is substantial. Proceed with calibrated expectations.

For readers considering Biotinoyl Tripeptide-1, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Biotinoyl Tripeptide-1

Further Reading and Resources

If you want to go deeper on Biotinoyl Tripeptide-1, the evidence landscape for hair & follicle peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Hair & Follicle Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Biotinoyl Tripeptide-1 — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Pickart L. "The human tri-peptide GHK and tissue remodeling." J Biomater Sci Polym Ed. 2008;19(8):969–988. PMID 18644225
2. Pickart L, et al. "GHK tripeptide stimulates collagen synthesis in human dermal fibroblasts." In vitro fibroblast model data. PMID 11133367
3. Pyo HK, et al. "The effect of tripeptide-copper complex on human hair growth in vitro." Arch Pharm Res. 2007;30(7):834–839. PMID 17703734
4. Uno H, Kurata S. "Chemical agents and peptides affect hair growth." J Invest Dermatol. 1993;101(1 Suppl):143S–147S. PMID 1809108
5. Liezmann C, et al. "Substance P and vasoactive intestinal peptide differentially modulate human hair follicle immune privilege." J Invest Dermatol. 2011;131(Suppl 2):abstract. PMID 21702037
6. Patel DP, et al. "A review of the use of biotin for hair loss." Skin Appendage Disord. 2017;3(3):166–169. PMID 28879195
7. Walth CB, et al. "Biotin for hair loss: teasing out the evidence." J Am Acad Dermatol. 2024. PMID 39148962
8. Samadi A, et al. "Assessment of the efficacy and tolerability of a topical formulation containing caffeine and Procapil 3% for improvement of male pattern hair loss." J Cosmet Dermatol. 2024;23(4):1492–1494. PMID 37990760
9. Comparative study: Procapil+PRP vs. Redensyl+PRP for androgenetic alopecia. Cureus. 2023. PMID 37292551
10. Pickart L, Thaler MM. "Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic cells." Nat New Biol. 1973;243(124):85–87. (Discovery of GHK)

---